Reports
Reports
The global insulin pens market is expected to grow at a CAGR of 7.30% between 2023 and 2028. Key market drivers include increasing prevalence of diabetes, easy applications, and improvements in healthcare infrastructure at a global level.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Insulin pens are pen-shaped devices with an injector and a reservoir where insulin can be stored. Available in disposable and reusable formats, insulin pens are used by people with diabetes who require insulin in a liquid form. Insulin pens are increasingly replacing insulin syringes because they are less painful and are easier to use as compared to the conventional syringe. Insulin pens are mostly injected in the front and side of thigh, in the abdomen, and in the outer and upper arms.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Based on product type, the market can be bifurcated into prefilled and reusable. By end use, the market is categorised into hospitals and clinics, ambulatory surgical centres, and home care setting. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.
The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis. The report gives a detailed analysis of the following key players in the global insulin pens market covering their competitive landscape and latest developments like mergers, acquisitions, investments, and expansion plans.
Hospitals and clinics accounted for a significant share in the insulin pens market globally because they have skilled doctors and professionals with fully equipped products to diagnose and treat both type 1 and type 2 diabetic patients. Furthermore, in healthcare settings, a new insulin pen is required for every patient at every visit, increasing the number of pens used in hospitals and clinics. Patients are provided with insulin timely to improve their blood sugar levels, often in critical situations. However, home care settings are a growing end use segment for insulin pens as more people become regular users of insulin and switch to insulin pens instead of syringes.
North America held the sizable share in the global insulin pens market owing to the widespread prevalence of diabetes in the region. Presence of a large number of key players and increasing research and development activities by them in order to improve insulin pen features and capabilities are enhancing the growth of the market in the region. Moreover, demand for smart insulin delivery products is increasing rapidly which is encouraging the manufacturers to come up with new solutions in order to fulfil their demand. In countries such as the United States, insulin pens are among the most forms of insulin delivery used by patients.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Eli Lilly and Company was established in 1876 and is headquartered in Indiana in the United States. It is a pharmaceutical company that carries out research and development to improve its product offerings for its customers and consumers. Eli Lilly and Company manufactures human healthcare products such as clinical depression drugs and antipsychotic medications, among other products.
Novo Nordisk A/S was founded in 1923 is headquartered in Bagsvaerd, Denmark. It is a Danish pharmaceutical company that innovates and develops biological medicines for the healthcare industry. Their products include medicines for conditions such as diabetes, haemophilia, obesity, hormone replacement, and growth hormone therapy. Beyond medicine development, they aim to make their product accessible to every person throughout the world.
Biocon Limited was founded in 1978 and has its headquarter in Bengaluru, India. It is a pharmaceutical company that is involved in developing biosimilars, complex APIs, and generic formulations, and supplying these products and solutions to consumers globally. It is also known for commercialising recombinant human insulin using a yeast expression system.
Other market players include F. Hoffmann-La Roche Ltd., Sanofi-aventis Groupe, and Becton, Dickinson and Company, among others.
REPORT FEATURES | DETAILS |
---|---|
Base Year | 2022 |
Historical Period | 2018-2022 |
Forecast Period | 2023-2028 |
Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
Breakup by Product Type |
|
Breakup by Disease Type |
|
Breakup by Distribution Channel |
|
Breakup by Region |
|
Market Dynamics |
|
Supplier Landscape |
|
Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Insulin Pens Market Overview
3.1 Global Insulin Pens Market Historical Value (2016-2022)
3.2 Global Insulin Pens Market Forecast Value (2023-2031)
4 Global Insulin Pens Market Landscape
4.1 Global Insulin Pens Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Insulin Pens Product Landscape
4.2.1 Analysis by Product Type
4.2.2 Analysis by Disease Type
4.2.3 Analysis by Distribution Channel
5 Global Insulin Pens Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Insulin Pens Market Segmentation
6.1 Global Insulin Pens Market by Product Type
6.1.1 Market Overview
6.1.2 Disposable Insulin Pen
6.1.3 Reusable Insulin Pen
6.2 Global Insulin Pens Market by Disease Type
6.2.1 Market Overview
6.2.2 Type I Diabetes
6.2.3 Type II Diabetes
6.3 Global Insulin Pens Market by Distribution Channel
6.3.1 Market Overview
6.3.2 Hospital Pharmacy
6.3.3 Retail Pharmacy
6.3.4 Online Pharmacy
6.3.5 Diabetes Clinics
6.3.6 Others
6.4 Global Insulin Pens Market by Region
6.4.1 Market Overview
6.4.2 North America
6.4.3 Europe
6.4.4 Asia Pacific
6.4.5 Latin America
6.4.6 Middle East and Africa
7 North America Insulin Pens Market
7.1 Market Share by Country
7.2 United States of America
7.3 Canada
8 Europe Insulin Pens Market
8.1 Market Share by Country
8.2 United Kingdom
8.3 Germany
8.4 France
8.5 Italy
8.6 Others
9 Asia Pacific Insulin Pens Market
9.1 Market Share by Country
9.2 China
9.3 Japan
9.4 India
9.5 ASEAN
9.6 Australia
9.7 Others
10 Latin America Insulin Pens Market
10.1 Market Share by Country
10.2 Brazil
10.3 Argentina
10.4 Mexico
10.5 Others
11 Middle East and Africa Insulin Pens Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.4 Nigeria
11.5 South Africa
11.6 Others
12 Patent Analysis
12.1 Analysis by Type of Patent
12.2 Analysis by Publication year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players
13 Grants Analysis
13.1 Analysis by year
13.2 Analysis by Amount Awarded
13.3 Analysis by Issuing Authority
13.4 Analysis by Grant Application
13.5 Analysis by Funding Institute
13.6 Analysis by NIH Departments
13.7 Analysis by Recipient Organization
14 Funding Analysis
14.1 Analysis by Funding Instances
14.2 Analysis by Type of Funding
14.3 Analysis by Funding Amount
14.4 Analysis by Leading Players
14.5 Analysis by Leading Investors
14.6 Analysis by Geography
15 Partnership and Collaborations Analysis
15.1 Analysis by Partnership Instances
15.2 Analysis by Type of Partnership
15.3 Analysis by Leading Players
15.4 Analysis by Geography
16 Regulatory Framework
16.1 Regulatory Overview
16.1.1 US FDA
16.1.2 EU EMA
16.1.3 INDIA CDSCO
16.1.4 JAPAN PMDA
16.1.5 Others
17 Supplier Landscape
17.1 Nikkiso Co., Ltd.
17.1.1 Financial Analysis
17.1.2 Product Portfolio
17.1.3 Demographic Reach and Achievements
17.1.4 Mergers and Acquisitions
17.1.5 Certifications
17.2 Asahi Kasei Medical Co. Ltd
17.2.1 Financial Analysis
17.2.2 Product Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisitions
17.2.5 Certifications
17.3 B. Braun Melsungen AG
17.3.1 Financial Analysis
17.3.2 Product Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisitions
17.3.5 Certifications
17.4 Fresenius SE & Co. KGaA
17.4.1 Financial Analysis
17.4.2 Financial Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisitions
17.4.5 Certifications
17.5 Terumo Bct, Inc
17.5.1 Financial Analysis
17.5.2 Product Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisitions
17.5.5 Certifications
17.6 Haemonetics Corporation
17.6.1 Financial Analysis
17.6.2 Product Portfolio
17.6.3 Demographic Reach and Achievements
17.6.4 Mergers and Acquisitions
17.6.5 Certifications
17.7 Mallinckrodt
17.7.1 Financial Analysis
17.7.2 Product Portfolio
17.7.3 Demographic Reach and Achievements
17.7.4 Mergers and Acquisitions
17.7.5 Certifications
17.8 Kaneka Corporation
17.8.1 Financial Analysis
17.8.2 Product Portfolio
17.8.3 Demographic Reach and Achievements
17.8.4 Mergers and Acquisitions
17.8.5 Certifications
17.9 Kawasumi Laboratories, Inc.
17.9.1 Financial Analysis
17.9.2 Product Portfolio
17.9.3 Demographic Reach and Achievements
17.9.4 Mergers and Acquisitions
17.9.5 Certifications
17.10 Miltenyi Biotec
17.10.1 Financial Analysis
17.10.2 Product Portfolio
17.10.3 Demographic Reach and Achievements
17.10.4 Mergers and Acquisitions
17.10.5 Certifications
17.11 Infomed
17.11.1 Financial Analysis
17.11.2 Product Portfolio
17.11.3 Demographic Reach and Achievements
17.11.4 Mergers and Acquisitions
17.11.5 Certifications
17.12 Toray Medical Co., Ltd.
17.12.1 Financial Analysis
17.12.2 Product Portfolio
17.12.3 Demographic Reach and Achievements
17.12.4 Mergers and Acquisitions
17.12.5 Certifications
18 Global Insulin Pens Market - Distribution Model (Additional Insight)
18.1 Overview
18.2 Potential Distributors
18.3 Key Parameters for Distribution Partner Assessment
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
21.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
The market is expected to grow at a CAGR of 7.30% between 2023 and 2028.
The major market drivers are increasing prevalence of diabetes, easy to use nature of insulin pens, and improvements in global healthcare infrastructure.
The key trends of the market are increase growing affordability of insulin pens, preference for refillable insulin pens in home settings, and technological advancements such as the development of smart insulin pens.
Key players in the insulin pens market include Eli Lilly and Company, Novo Nordisk A/S, Biocon Limited, F. Hoffmann-La Roche Ltd., Sanofi-aventis Groupe, and Becton, Dickinson and Company, among others.
An insulin pen is an injector device in the shape of a pen with a reservoir to store insulin that is used to inject insulin in people suffering from diabetes.
Insulin pens are considered less painful than insulin syringes and are easier to use and carry.
The market for insulin pens is segmented based on product type, end use, and region.
Insulin pens can be injected in the front and side of thigh, in the abdomen, and in the outer and upper arms.
The primary product types for insulin pens are prefilled and reusable.
The various end uses in the market are hospitals and clinics, ambulatory surgical centres, and home care settings.
Mini Report
Single User License
Five User License
Corporate License
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.